HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Dorzagliatin

HCID 57920094
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1191995-00-2
Standard SMILES
CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=O
InChIKey
HMUMWSORCUWQJO-QAPCUYQASA-N
Molecular formula
C22H27ClN4O5
Average molar mass
462.9 g/mol
Monoisotopic mass
462.1669977

Overview

Dorzagliatin is a secondary carboxamide resulting from the formal condensation of the carboxy group of (2S)-2-[4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-4-methylpentanoic acid with the amino group of (2R)-3-(3-amino-1H-pyrrol-1-yl)propane-1,2-diol. It is an allosteric glucokinase activator developed by Hua Medicine for the treatment of type 1 and 2 diabetes mellitus , and diabetic kidney disease. It has a role as an enzyme activator and a hypoglycemic agent. It is a secondary carboxamide, a primary alcohol, a pyrroline, a diol, a member of pyrazoles, an aromatic ether, a secondary alcohol, a tertiary amino compound, an enone and a member of monochlorobenzenes.

Names & identifiers

Preferred name
Dorzagliatin
IUPAC
(2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide
English name
Dorzagliatin
Molecular formula
C22H27ClN4O5
Molecular weight
462.93

Names & synonyms

Dorzagliatin1191995-00-2HMS5552HMS-5552SinogliatindorzagliatinadorzagliatinedorzagliatinumRO5305552RO-5305552X59W6980E8(2S)-2-[4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl]-N-{1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl}-4-methylpentanamide
Show more names
Dorzagliatin Impurity 8Dorzagliatin, 10 mM in DMSODorzagliatin (Synonyms: HMS5552)(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihyddiabetes,inhibit,β-cell,Hexokinase IV,Inhibitor,glycaemic,type 2,Hexokinase D,Glucokinase,Dorzagliatin,pancreatic,HMS-5552,HMS 5552(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide
(2S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((2R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-methylpentanamide1H-Pyrrole-1-acetamide, 4-(2-chlorophenoxy)-N-(1-((2R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-2,5-dihydro-alpha-(2-methylpropyl)-2-oxo-, (alphaS)-RefChem:135682Dorzagliatin [INN](S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-MethylpentanaMideMFCD22376579AKOS030527745(2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide

Database identifiers

CAS
1191995-00-2
PubChem CID
57920094
ChEMBL
CHEMBL4297508
ChEBI
CHEBI:234514
UNII
X59W6980E8
Nikkaji
J3.762.832H

Properties

Computed structural properties

XLogP
1.6
Topological polar surface area
117 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
6
Rotatable bonds
10
Heavy atoms
32
Formal charge
0
Complexity
691

Physicochemical properties

Boiling point
761.7 · 761.7±60.0 °C(Predicted)
Density
1.38 · 1.38±0.1 g/cm3(Predicted)
solubility
108.5 · DMSO:108.5(Max Conc. mg/mL);234.38(Max Conc. mM)Ethanol:92.0(Max Conc. mg/mL);198.73(Max Conc. mM)
pka
12.84 · 12.84±0.70(Predicted)
form
Solid
color
White to off-white
FDA UNII
59 W6980E8 · X59W6980E8
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H319
Precautionary statements
P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Chemistry & industry

Pharmacology

ATC Code · 2 items

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Applications · 2 items

DescriptionDorzagliatin (trade name HuaTangNing) is a first-in-class small molecule oral glucokinase activator (GKA) developed by Hua Medicine for the treatment of diabetic nephropathy (DKD), type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Dorzagliatin was first approved in China in September 2022 as a monotherapy or in combination with metformin, an antidiabetic drug, for adults with type 2 diabetes.

UsesDorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes[1].

Related reactions

1 records
New reaction record
HRID 19003 reaction equation
HRID 19003As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes